Anish Bhatnagar has been the CEO of Soleno Therapeutics since February 2014. Before that, he climbed the ranks from President and COO, starting his journey with the company in 2006. His background is in medicine, having earned his medical degree...

Anish Bhatnagar has been the CEO of Soleno Therapeutics since February 2014. Before that, he climbed the ranks from President and COO, starting his journey with the company in 2006. His background is in medicine, having earned his medical degree at SMS Medical College in India. He has over 15 years of experience in the medical device and biopharmaceutical industries, working on biologics, drugs, and medical devices. He previously worked at companies like Coulter Pharmaceuticals and Titan Pharmaceuticals. His compensation reflects a significant increase over the years, earning over $1 million in total compensation recently, including a sizable bonus this past year. What's notable is his deep involvement in R&D and a commitment to driving company performance, aligning his interests closely with the shareholders.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

S

Anish Bhatnagar

CEO of Soleno Therapeutics

Education

Medical degree at SMS Medical College in Jaipur, India

Field of Expertise

Healthcare & Life Sciences - Medicine

Sector of Economy

Healthcare

Born

January 1, 1974 - 51 years ago

CEO of Soleno Therapeutics for

11 years 4 months (Feb 2014 - Present)

Previous Experience

President and Chief Operating Officer at Soleno Therapeutics, Inc.

Rivals

Competitors/colleagues of Anish Bhatnagar

Holdings

See how much did Anish Bhatnagar make over time.

Dr. Anish Bhatnagar's financial holdings show considerable fluctuations over recent years. His stake in Soleno Therapeutics has varied, reaching significant peaks around mid-2020, where his insider trading hovered between $700K and $1.3M monthly. As of late 2021, his trading slowed,...

Dr. Anish Bhatnagar's financial holdings show considerable fluctuations over recent years. His stake in Soleno Therapeutics has varied, reaching significant peaks around mid-2020, where his insider trading hovered between $700K and $1.3M monthly. As of late 2021, his trading slowed, indicating a shift from active trading strategies to possibly a long-term outlook. Over the past few years, trading values have ranged from $30K to as high as $7M, illustrating a dynamic relationship with his company’s stock. This fluctuation echoes his strategic focus on the company’s long-term health rather than short-term gains, which aligns with his leadership style and vision for Soleno.

Mar 11, 2025

S

shares

SLNO @ $44.03

Total Stock Sold

$18.82M

SLNO

$18.82M

460,342.2 SLNO shares

What if they kept their stock?

If Anish Bhatnagar didn't sell their stock, today they would have:
Extra SLNO460,342.2 shares worth $12.22M.
This is -35.07% and $6.60M less than what they got when they sold the stock.

Insider Trading

See recent insider trades of Anish Bhatnagar.

SLNO

$5.47M

SLNO at $47.55/share

Aug 28, 2024

Sale

SLNO

$5.77M

SLNO at $45.28/share

Aug 5, 2024

Sale

SLNO

850,000 shares

SLNO

Jul 17, 2024

Received

SLNO

$797.65K

SLNO at $41.42/share

Jul 1, 2024

Sale

SLNO

$785.68K

SLNO at $41.39/share

Apr 1, 2024

Sale

SLNO

$122.05K

SLNO at $48.30/share

Jan 25, 2024

Sale

SLNO

150,000 shares

SLNO

Jan 4, 2024

Received

SLNO

$3.37M

SLNO at $36.09/share

Dec 11, 2023

Sale

SLNO

$794.12K

SLNO at $28.65/share

Nov 30, 2023

Sale

SLNO

$1.48M

SLNO at $27.58/share

Nov 28, 2023

Sale

Compensation History

See how much did Anish Bhatnagar make over time.

In 2023, Anish Bhatnagar made headlines with a total compensation of approximately $4.12 million, a considerable jump from his past earnings. His salary was stable at about $556,800. He received a bonus of $500,000, reflecting his effectiveness in leading the company through challenges. The bulk of his compensation came from stock options, which illustrate confidence in the company’s future by tying part of his pay to performance. Over the years, his pay structure has shifted, with bonuses and stock options playing larger roles compared to earlier years where his compensation was more straightforward. This shift signifies a more results-driven approach to executive pay as the company matures in the market.

Year

2023

Total Compensation

$1.06M

Salary

$556.80K

Board Justification

The compensation philosophy aligns with company performance, peer benchmarking, and retention strategies, focusing on attracting and retaining top talent in the biopharmaceutical industry.

Bonus

$500.00K

Board Justification

Bonus awards for executives are accrued ratably throughout the year and are subject to review and approval by the Compensation Committee of the Board of Directors subsequent to the year in which they are earned and accrued.

Other

$0.00

Board Justification

No other compensation was reported for 2023.

Restricted Stock

$0.00(0 Common Stock)

Board Justification

No stock was reported as vested in 2023.

Performance Metrics

The performance metrics determining the compensation include company-wide performance goals and individual contributions.